+217.7%
TEL vs MRNA
+521.0%
-303.3%
-46.9%
Performance
Returns, benchmark comparison, and relative performance.
Performance by timeframe
Returns for all.
| Period | Portfolio | MRNA | Excess | Alpha |
|---|---|---|---|---|
| 1D | 0.0% | +0.7% | -0.8% | -0.1% |
| 7D | -2.3% | -8.2% | +5.9% | -1.9% |
| 30D | -6.1% | +125.6% | -131.6% | -12.6% |
| 3M | +1.7% | +197.1% | -195.4% | -7.8% |
| 6M | +1.6% | +148.5% | -146.9% | -6.7% |
| YTD | -9.1% | +363.3% | -372.4% | -20.7% |
| 1Y | -1.7% | +462.0% | -463.7% | -15.7% |
| 3Y | +67.3% | +26.9% | +40.4% | +53.4% |
| 5Y | +52.1% | -69.6% | +121.7% | +41.3% |
| All | +217.7% | +521.0% | -303.3% | +191.2% |
Cumulative growth
Daily Returns
Daily percentage return beside MRNA.
Daily Out/Under-Performance
Portfolio return minus MRNA return. Positive bars indicate outperformance.
Daily Alpha
Portfolio daily return minus β × MRNA return. Early observations use the first valid beta; later observations use the trailing beta estimated for each date.
Cumulative Out/Under-Performance
Relative wealth over all: compounded portfolio wealth divided by compounded MRNA wealth, less one. Both series rebase at the selected span's start.
Cumulative Alpha
Compounded beta-adjusted residual returns apply the first valid beta to early observations, then the trailing beta ending on each date.
Updating return analytics…
all analysis · Full analysis span regression · 6 months rolling